ClinicalTrials.Veeva

Menu

Effect of Gutamine Administration in the Innate Immune System Response in ICU Patients.

H

Hospital Universitari Son Dureta

Status

Completed

Conditions

Injury Severity Score (ISS) > 12 Points Were Included in the Study.
Moderate to Severe Trauma, as Defined by an

Treatments

Other: Total Parenteral Nutrition without glutamine
Dietary Supplement: Total Parenteral Nutrition with Glutamine

Study type

Interventional

Funder types

Other

Identifiers

NCT01250080
IB709/06

Details and patient eligibility

About

Glutamine is the most abundant nonessential amino acid in the human body. Besides its role as a constituent of proteins and its importance in amino acid transamination, glutamine may modulate immune cells.

The innate immune system is the first line of host defence against pathogens and in most cases sufficient to eliminate invading microbes. Mammalian Toll-like receptors (TLR) comprise a family of germ line-encoded trans-membrane receptors which activation leads to the induction of inflammatory responses, phagocytosis but also to the development of antigen specific adapative immunity.

It has been postulated though not formally proven yet that glutamine beneficial effect could be due to a positive effect on the innate immune system. Given the importance of TLRs and TLRs-dependent signalling in host defence against infections we hypothesized that glutamine may increase the expression and/or functionality of TLRs which in turn may have beneficial effects to clear infections.

Full description

Objective: To evaluate whether glutamine supplementation alters the expression and functionality of TLR2 and TLR4 in circulating monocytes of trauma patients admitted to the ICU. Specifically the next variables were measured:

  • Expression of TLR2 and TLR4 in peripheral blood monocytes was determined by flow cytometry
  • To study the functionality of TLR2 and TLR4, monocytes were stimulated with TLR specific agonists and cytokines were measured in cell culture supernatants. We determined the concentration of IL-1β, IL-6, TNFα and IL-10 in cell culture supernatants using a bead array ELISA.
  • To determine the phagocytic capability of monocytes, live Escherichia coli expressing green fluorescent protein was added to 100 μL of whole blood collected in K2-anticoagulation medium tubes. Bacteria were added at a ratio of 100 bacteria per monocyte. The analyses were carried out in an Epics XL flow cytometer.

Enrollment

43 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age between 18 and 75 years (inclusive).
  • Moderate to severe trauma, as defined by an Injury Severity Score (ISS) > 12 points were included in the study
  • Traumatic patients who required total parenteral nutrition

Exclusion criteria

  • Patients who were under 17 and over 76 years of age,
  • Patients whose life expectancy was less than 5 days
  • Patientes allergic to glutamine.
  • Patients with any basic pathology included any serious immune system condition (diabetes, HIV, lupus, etc.) or who, in their long-term treatment prior to admission to ICU, received corticoids or any other immunosuppressant medication.
  • Pregnant women.

Trial design

43 participants in 2 patient groups

Glutamine
Experimental group
Treatment:
Dietary Supplement: Total Parenteral Nutrition with Glutamine
Control
Sham Comparator group
Treatment:
Other: Total Parenteral Nutrition without glutamine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems